CANTHEL

Canthel Biomedical is a UK-based biotechnology company focused on the discovery and development of first-in-class small molecule inhibitors for the treatment of cancer. A spin-out from the University of Manchester, the company targets the enzyme Calcium-activated nucleotidase 1 (CANT1), which is overexpressed in several aggressive malignancies. Its primary focus is on Desmoplastic Small Round Cell Tumor (DSRCT), a rare and often fatal pediatric cancer, as well as prostate cancer. By inhibiting CANT1, Canthel aims to provide new therapeutic options for patients with limited treatment alternatives. The company's approach leverages deep expertise in cancer biology and medicinal chemistry to disrupt tumor growth and survival pathways.